AMSTERDAM, 30 avr. 2025 (GLOBE NEWSWIRE) — DEBRICHEM®, le produit phare de DEBx Medical, a obtenu le prix IIWCG Achievement Award 2025 récompensant l’innovation dans le [...] Read more »
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) — DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 for Innovation in Wound Care at the [...] Read more »
Minovia Therapeutics Announces FDA Clearance of Second IND Application, for a Phase II Clinical Trial of Lead Product MNV-201 in Pearson Syndrome
MNV–201 is Minovia’s second generation mitochondrial cell therapy product composed of autologous hematopoietic stem cells enriched with allogeneic mitochondria
Read more »
Society for Clinical Research Sites (SCRS) und Fortrea gehen eine Partnerschaft zur Förderung der Zusammenarbeit in der klinischen Forschung ein
DURHAM, North Carolina, Feb. 20, 2025 (GLOBE NEWSWIRE) — Die Society for Clinical Research Sites (SCRS) und Fortrea (Nasdaq: FTRE), ein führendes globales Auftragsforschungsinstitut (Contract Research Organization, [...] Read more »
La Society for Clinical Research Sites (SCRS) et Fortrea s’associent pour promouvoir la collaboration dans le domaine de la recherche clinique
DURHAM, N.C., 20 févr. 2025 (GLOBE NEWSWIRE) — La Society for Clinical Research Sites (SCRS) et Fortrea (Nasdaq : FTRE), l’une des principales organisations de recherche contractuelle (ORC) à [...] Read more »
Society for Clinical Research Sites (SCRS) e Fortrea Fazem Parceria para Promover a Colaboração na Pesquisa Clínica
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — A Society for Clinical Research Sites (SCRS) e a Fortrea (Nasdaq: FTRE), uma organização líder global de pesquisa por contrato (CRO), tem o prazer de anunciar o [...] Read more »
Society for Clinical Research Sites (SCRS) and Fortrea Partner to Advance Collaboration in Clinical Research
DURHAM, N.C., Feb. 20, 2025 (GLOBE NEWSWIRE) — The Society for Clinical Research Sites (SCRS) and Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), are pleased to announce Fortrea’s [...] Read more »
EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY Accepted for Oral Presentation at World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases
JERUSALEM , Feb. 19, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptide and protein replacement therapies in tablet [...] Read more »
Workplace Options stellt umfassendes und engagiertes Wiedereingliederungsprogramm für Krebsüberlebende vor
RALEIGH, North Carolina, Jan. 24, 2025 (GLOBE NEWSWIRE) — Die Rückkehr an den Arbeitsplatz nach einer Krebsdiagnose ist mit vielen großen Herausforderungen verbunden – körperliche Erschöpfung, emotionale [...] Read more »
Workplace Options Lança Programa Abrangente e Compassivo de Retorno ao Trabalho para Sobreviventes de Câncer
RALEIGH, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) — O retorno ao trabalho após um diagnóstico de câncer é uma jornada repleta de desafios – fadiga física, obstáculos emocionais e [...] Read more »